Datavault AI Grants Scilex Exclusive License for Biotech Asset Tokenization Platform
TL;DR
Datavault AI's exclusive license with Scilex creates a first-mover advantage in the $2 trillion biotech tokenization market with potential for $2.55 billion in milestone payments.
Datavault AI's technology enables tokenization of biotech assets through AI-driven blockchain solutions, creating exchange platforms for genomic data and pharmaceutical information.
This technology enables biotech companies to access non-dilutive funding, accelerating medical research and drug development for better healthcare outcomes worldwide.
Datavault AI's deal combines AI, blockchain, and biotech to create digital twins of pharmaceutical assets, revolutionizing how medical data is valued and traded.
Found this article helpful?
Share it with your network and spread the knowledge!
Datavault AI has granted Scilex Holding Company an exclusive worldwide license to deploy its proprietary AI-driven technology within the biotech and biopharma sectors. The agreement enables Scilex to build and operate a Biotech Exchange platform to tokenize, trade, and monetize biotech assets such as genomic data, diagnostics, and drug information. This strategic partnership represents a significant advancement in applying blockchain and artificial intelligence technologies to the life sciences industry.
The licensing arrangement includes substantial financial components, with a $10 million upfront payment structured in four installments and potential milestone payments reaching up to $2.55 billion. Datavault AI expects the technology to expand into a Pharmaceutical Exchange platform addressing an estimated $2 trillion market opportunity. This expansion would provide companies with innovative pathways to access non-dilutive funding, potentially transforming how biotech and pharmaceutical firms finance research and development activities.
The technology is supported by Datavault AI's broad patent portfolio and proven high-performance computing expertise. The company's platform leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization. Additional information about the company's technology can be found at https://www.datavaultsite.com. The Information Data Exchange enables Digital Twins and licensing of name, image, and likeness by securely attaching physical real-world objects to immutable metadata objects.
This licensing agreement represents a major step in bridging advanced technology with the biopharmaceutical industry, potentially creating new paradigms for asset valuation and monetization in healthcare. The integration of AI-driven blockchain solutions could revolutionize how biotech companies manage and capitalize on their intellectual property and research assets. The platform's ability to tokenize complex biotech assets positions it as a potential game-changer in an industry increasingly focused on data-driven innovation and alternative financing models.
Curated from NewMediaWire
